Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles

Zhu, Zhouyu; Yu, Tao; Chai, Ying

doi:10.18632/oncotarget.13046

Cited by 7 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 9 In 35%~60% of MPLC patients, TP53 gene mutations can be used to determine whether the clonal origin of each lesion is the same. 10 In this case, TP53 mutations were different in the two lesions, which verified their different sources. A genomic analysis based on NENs patients in China showed that co‐mutations of TP53 and RB1were detected in 95% of SCLCs.…”

Section: Discussionsupporting

confidence: 55%

“…Mutations in the tumor protein p53 (TP53) gene and RB transcriptional corepressor 1 (RB1) gene are common in high‐grade lung neuroendocrine tumors 9 . In 35%~60% of MPLC patients, TP53 gene mutations can be used to determine whether the clonal origin of each lesion is the same 10 . In this case, TP53 mutations were different in the two lesions, which verified their different sources.…”

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

A case of bilateral synchronous double primary lung cancer secondary to bladder cancer: From the next‐generation sequencing prospect

et al. 2023

View full text Add to dashboard Cite

One year following bladder cancer surgery, a 65‐year‐old man had computed tomography (CT) that revealed bilateral pulmonary nodules. Pulmonary wedge resections were performed after the nodules were found to grow in follow‐up. Unusually, we found that these two lesions were not homologous, nor were they metastases from prior bladder cancer, and therefore, synchronous double primary lung cancer (sDPLC) was diagnosed. The immunohistochemical findings excluded the possibility of bladder cancer metastasis, but could not determine whether they were from the same source. Next generation sequencing (NGS) supported the diagnosis sDPLC because they amply demonstrated the two sources’ distinct origins. Finally, after discussion with pathologists, this patient was diagnosed as small cell lung carcinoma (SCLC) and received postoperative EP chemotherapy. We also documented a few rather uncommon alterations that might serve as a foundation for further investigation. This case suggests that in addition to immunohistochemical, NGS is also helpful to clarify the etiology and refine the pathological classification of tumors, which has guiding significance for the establishment of precise diagnosis and optimal treatment.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 90%

A case of bilateral synchronous double primary lung cancer secondary to bladder cancer: From the next‐generation sequencing prospect

et al. 2023

View full text Add to dashboard Cite

show abstract

“…While the left lobe lesions responded to TKI, the poorly differentiated lesion of the right lobe progressed. After resection of the right lobe, the tissue was subjected to mutation analysis, which revealed a PTEN mutation, but no EGFR mutations [94]. PTEN proficient HCC827 cells with the sensitizing to-TKI-therapy EGFR mutation showed high sensitivity to gefitinib.…”

Section: Pten-mediated Resistance To Targeted Therapymentioning

confidence: 99%

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around

Gkountakos

Sartori

Falcone

et al. 2019

Cancers

View full text Add to dashboard Cite

Lung cancer is the most common malignancy and cause of cancer deaths worldwide, owing to the dismal prognosis for most affected patients. Phosphatase and tensin homolog deleted in chromosome 10 (PTEN) acts as a powerful tumor suppressor gene and even partial reduction of its levels increases cancer susceptibility. While the most validated anti-oncogenic duty of PTEN is the negative regulation of the PI3K/mTOR/Akt oncogenic signaling pathway, further tumor suppressor functions, such as chromosomal integrity and DNA repair have been reported. PTEN protein loss is a frequent event in lung cancer, but genetic alterations are not equally detected. It has been demonstrated that its expression is regulated at multiple genetic and epigenetic levels and deeper delineation of these mechanisms might provide fertile ground for upgrading lung cancer therapeutics. Today, PTEN expression is usually determined by immunohistochemistry and low protein levels have been associated with decreased survival in lung cancer. Moreover, available data involve PTEN mutations and loss of activity with resistance to targeted treatments and immunotherapy. This review discusses the current knowledge about PTEN status in lung cancer, highlighting the prevalence of its alterations in the disease, the regulatory mechanisms and the implications of PTEN on available treatment options.

show abstract

“…recommend extensive molecular profiling in cases with multiple lung cancers, as it might clarify the association between the lung lesions found . Several investigators have reported the utility of molecular biological analysis for diagnosis and treatment in multiple primary cancers, not only in lung cancer but also breast, gastric, hepatocellular, renal, and colorectal cancers . Thus, molecular biological analysis is necessary when multiple cancers of the same histotype are identified in the same tissue where there are multiple primary tumors.…”

Section: Discussionmentioning

confidence: 99%

Molecular biological analysis in a patient with multiple lung adenocarcinomas

et al. 2018

View full text Add to dashboard Cite

The utility of molecular biological analysis in lung adenocarcinoma has been demonstrated. Herein we report a rare case presenting as multiple lung adenocarcinomas with four different EGFR gene mutations detected in three lung tumors. After opacification was detected by routine chest X‐ray, the patient, a 64‐year‐old woman, underwent chest computed tomography which revealed a right lung segment S4 ground‐glass nodule (GGN). Follow‐up computed tomography revealed a 42 mm GGN nodule with a 26 mm nodule (S6) and a 20 mm GGN (S10). Histopathology of resected specimens from the right middle and lower lobes revealed all three nodules were adenocarcinomas. Four EGFR mutations were detected; no three tumors had the same mutations. Molecular biological analysis is a promising tool for the diagnosis of primary tumors in patients with multiple lung carcinomas of the same histotype, enabling appropriate treatment.

show abstract

Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles

Cited by 7 publications

References 7 publications

A case of bilateral synchronous double primary lung cancer secondary to bladder cancer: From the next‐generation sequencing prospect

A case of bilateral synchronous double primary lung cancer secondary to bladder cancer: From the next‐generation sequencing prospect

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around

Molecular biological analysis in a patient with multiple lung adenocarcinomas

Contact Info

Product

Resources

About